Myelodysplastic syndromes

Annual Review of Medicine

Volumn 61, Issue , 2010, Pages 345-358

  Scott, Bart L ^a   Deeg, H Joachim ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Azacitidine; Decitabine; Lenalidomide; MDS; Stem cell transplantation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTHRACYCLINE; AZACITIDINE; CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEFERASIROX; ERYTHROPOIETIN; FERRITIN; FLUDARABINE; FOLIC ACID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOGLOBIN; HLA DR ANTIGEN; IDARUBICIN; IRON; IRON CHELATING AGENT; LENALIDOMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; THYMOCYTE ANTIBODY; THYROTROPIN; TOPOTECAN; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ALCOHOL CONSUMPTION; BLEEDING; BLOOD CELL COUNT; BLOOD EXAMINATION; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER REGRESSION; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ASSESSMENT; COHORT ANALYSIS; CYANOCOBALAMIN DEFICIENCY; CYTOGENETICS; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG DOSE REDUCTION; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; EYE DISEASE; FERRITIN BLOOD LEVEL; FLOW CYTOMETRY; FOLIC ACID DEFICIENCY; GRANULOCYTOPENIA; HEARING DISORDER; HEARING TEST; HUMAN; IMMUNOMODULATION; INFECTION; IRON BINDING CAPACITY; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; KARYOTYPE; LIVER TOXICITY; LOW DRUG DOSE; MACROCYTIC ANEMIA; MYELOBLAST; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROGNOSIS; RECOMMENDED DRUG DOSE; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA AND RINGED SIDEROBLASTS; RETICULOCYTE COUNT; REVIEW; RISK BENEFIT ANALYSIS; STEM CELL TRANSPLANTATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT DURATION; UNITED STATES; VISION TEST; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MORTALITY; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; SURVIVAL RATE;

EID: 77951915308     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.051308.132852     Document Type: Review

References (60)

1. Rollison DE, Howlader N, Smith MT, et al. 2008. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 112:45-52
2. Ma X, Does M, Raza A, et al. 2007. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 109:1538-1542
3. Bennett JM, Catovsky D, Daniel MT, et al. 1982. The French-American- British (FAB) Co-Operative Group. Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 51:189-199
4. Vardiman JW, Harris NL, Brunning RD. 2002. The World Health Organization (WHO) classification of the myeloid neoplasms (review). Blood 100:2292-2302
5. Malcovati L, Porta MG, Pascutto C, et al. 2005. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J. Clin. Oncol. 23:7594-7603
6. Howe RB, Porwit-MacDonald A, Wanat R, et al. 2004. The WHO classification of MDS does make a difference. Blood 103:3265-3270
7. Greenberg P, Cox C, LeBeau MM, et al. 1997. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-88; erratum 91(3):1100
8. Malcovati L, Della Porta MG, Cazzola M. 2006. Predicting survival and leukemia evolution in patients with myelodysplastic syndrome. Haematologica 91:1588-1590
9. Malcovati L, Germing U, Kuendgen A, et al. 2007. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J. Clin. Oncol. 25:3503-3510
10. Haase D, Germing U, Schanz J, et al. 2007. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110:4385-4395
11. Kuendgen A, Gattermann N, Germing U. 2009. Improving the prognostic evaluation of patients with lower risk myelodysplastic syndromes. Leukemia 23:182-184
12. Park MJ, Kim HJ, Kim SH, et al. 2008. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS. Eur. J. Haematol. 81:364-373
13. Garcia-Manero G, Shan J, Faderl S, et al. 2008. A prognostic score for patients with lower risk myelodys-plastic syndrome. Leukemia 22:538-543
14. Buesche G, Teoman H, Wilczak W, et al. 2008. Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. Leukemia 22:313-322
15. Germing U, Hildebrandt B, Pfeilstocker M, et al. 2005. Refinementofthe international prognostic scoring system (IPSS) byincluding LDHas anadditional prognostic variableto improve risk assessmentin patients with primary myelodysplastic syndromes (MDS). Leukemia 19:2223-2231
16. Scott BL, Wells DA, Loken MR, et al. 2008. Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. Blood 112:2681-2686
17. vandeLoosdrecht AA, Westers TM, Westra AH,etal. 2008. Identificationofdistinct prognostic subgroups in low-and intermediate-1-risk myelodysplastic syndromes by flow cytometery. Blood 111:1067-1077
18. Van Bennekom CM, Abel G, Anderson T, et al. 2008. Patterns of treatment among patients with recently-diagnosed myelodysplastic syndromes in a national registry, 2006-2008. Blood 112(11):324, Abstr. #876
19. Yamaguchi N, Ito Y, Ohyashiki K. 2005. Increased intracellular activity of matrix metalloproteinases in neutrophils may be associated with delayed healing of infection without neutropenia in myelodysplastic syndromes. Ann. Hematol. 84:383-388
20. Zeidman A, Sokolover N, Fradin Z, et al. 2004. Platelet function and its clinical significance in the myelodysplastic syndromes. Hematol. J. 5:234-238
21. Negrin RS, Haeuber DH, Nagler A, et al. 1989. Treatment of myelodysplastic syndromes with recombi-nant human granulocyte colony-stimulating factor. A phase I-II trial. Ann. Intern. Med. 110:976-984
22. Thompson JA, Gilliland DG, Prchal JT, et al. 2000. Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodys-plastic syndrome. Blood 95:1175-1179
23. Rose C, Brechignac S, Vassilief D, et al. 2007. Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. A prospective analysis by the GFM. Blood 110(Pt. 1)(11):80a-81a, Abstr. #249
24. Leitch HA, Leger CS, Goodman TA, et al. 2008. Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy. Clin. Leuk. 2:205-211
25. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, et al. 2003. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br. J. Haematol. 120:1037-1046
26. Jädersten M, Montgomery SM, Dybedal I, et al. 2005. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood 106:803-811
27. Park S, Grabar S, Kelaidi C, et al., GFM Group. 2008. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 111:574-582
28. Miller KB, Kim HT, Greenberg P, et al. 2004. Blood 104(Pt. 1)(11):24a, Abstr. #70
29. JäderstenM, MalcovatiL,DybedalI, etal. 2008. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J. Clin. Oncol. 26:3607-3613
30. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, et al. 1998. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 92:68-75
31. Molldrem JJ, Leifer E, Bahceci E, et al. 2002. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndrome. Ann. Intern. Med. 137:156-163
32. Saunthararajah Y, Nakamura R, Wesley R, et al. 2003. A simple method to predict response to immuno-suppressive therapy in patients with myelodysplastic syndrome. Blood 102:3025-3027
33. Lim ZY, Killick S, Germing U, et al. 2007. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia 21:1436-1441
34. Stadler M, Germing U, Kliche KO, et al. 2004. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 18:460-465
35. Sloand EM, Wu CO, Greenberg P, et al. 2008. Factors affecting response and survival in patients with myelodysplasia treated with immunosupporessive therapy. J. Clin. Oncol. 26:2505-2511
36. Deeg HJ, Jiang PYZ, Holmberg LA, et al. 2004. Hematologic responses of patients with MDS to an-tithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. Leuk. Res. 28:1177-1180
37. Richardson PG, Schlossman RL, Weller E, et al. 2002. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100:3063-3067
38. List A, Dewald G, BennettJ, etal. 2006. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N. Engl. J. Med. 355:1456-1465
39. Raza A, Reeves JA, Feldman EJ, et al. 2008. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 111:86-93
40. Adès L, Boehrer S, Prebet T, et al. 2009. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood 113:3947-3952
41. Silverman LR, Demakos EP, Peterson BL, et al. 2002. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol. 20:2429-2440
42. Silverman LR, McKenzie DR, Peterson BL, et al., Leukemia Group. 2006. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J. Clin. Oncol. 24:3895-3903
43. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al., International Vidaza High-Risk MDS Survival Study Group. 2009. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 10:223-232
44. Kantarjian H, Issa JP, Rosenfeld CS, et al. 2006. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106:1794-1803
45. Kantarjian H, Oki Y, Garcia-Manero G, et al. 2007. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109:52-57
46. Wijermans P, Suciu S, Baila L, et al. 2008. Blood 112(11):90, Abstr. #226
47. Kantarjian H, Beran M, Cortes J, et al. 2006. Long-term follow-up results of the combination of topote-can and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer 106:1099-1109
48. Kantarjian HM, O'Brien S, Huang X, et al. 2007. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 109:1133-1137
49. Deeg HJ, Storer B, Slattery JT, et al. 2002. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100:1201-1207
50. Sorror ML, Sandmaier BM, Storer BE, et al. 2007. Comorbidity and disease status-based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J. Clin. Oncol. 25:4246-4254
51. Cutler CS, Lee SJ, Greenberg P, et al. 2004. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104:579-585
52. Martino R, Iacobelli S, Brand R, et al. 2006. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 108:836-846
53. Scott BL, Sandmaier BM, Storer B, et al. 2006. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 20:128-135
54. Chang CK, Storer BE, Scott BL, etal. 2007. Hematopoietic cell transplantation in patients with myelodys-plastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood 110:1379-1387
55. Alessandrino EP, Della Porta MG, Bacigalupo A, et al. 2008. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 112:895-902
56. Scott BL, Storer BE, Greene JE, et al. 2007. Marrow fibrosis as a risk factor for post-transplant outcome in patients with advanced MDS or AML with multilineage dysplasia. Biol. Blood Marrow Transplant 13:345-354
57. Armand P, Kim HT, Cutler CS, et al. 2007. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 109:4586-4588
58. Platzbecker U, Bornhäuser M, Germing U, et al. 2008. Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol. Blood Marrow Transplant 14:1217-1225
59. Scott BL, Park JY, Deeg HJ,etal. 2008. Pre-transplant neutropeniaisassociated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromes. Biol. Blood Marrow Transplant 14:799-806
60. Scott BL, Storer B, Loken M, et al. 2005. Pretransplantation induction chemotherapy and posttrans-plantation relapse in patients with advanced myelodysplastic syndrome. Biol. Blood Marrow Transplant 11:65-73